These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25577411)

  • 1. Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged.
    Timmer NM; Herbert MK; Claassen JA; Kuiperij HB; Verbeek MM
    Neurobiol Aging; 2015 Mar; 36(3):1271-3. PubMed ID: 25577411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
    Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
    Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
    Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
    J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal Fluid NrCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders--A Pilot Study.
    Müller M; Claassen JA; Kuiperij HB; Verbeek MM
    J Alzheimers Dis; 2015; 46(3):605-9. PubMed ID: 25812850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors.
    Schultz K; Nilsson K; Nielsen JE; Lindquist SG; Hjermind LE; Andersen BB; Wallin A; Nilsson C; Petersén A
    Eur J Neurol; 2010 Mar; 17(3):456-60. PubMed ID: 19922456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.
    Brunnström H; Rawshani N; Zetterberg H; Blennow K; Minthon L; Passant U; Englund E
    Alzheimers Dement; 2010 Mar; 6(2):104-9. PubMed ID: 20298970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
    J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease.
    Mollenhauer B; Bibl M; Trenkwalder C; Stiens G; Cepek L; Steinacker P; Ciesielczyk B; Neubert K; Wiltfang J; Kretzschmar HA; Poser S; Otto M
    J Neural Transm (Vienna); 2005 Jul; 112(7):933-48. PubMed ID: 15937638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
    Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
    J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
    Mollenhauer B; Cepek L; Bibl M; Wiltfang J; Schulz-Schaeffer WJ; Ciesielczyk B; Neumann M; Steinacker P; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
    Dement Geriatr Cogn Disord; 2005; 19(2-3):164-70. PubMed ID: 15637452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease?
    Tumani H; Shen G; Peter JB; Brück W
    Arch Neurol; 1999 Oct; 56(10):1241-6. PubMed ID: 10520940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased CSF α-synuclein levels in Alzheimer's disease: correlation with tau levels.
    Slaets S; Vanmechelen E; Le Bastard N; Decraemer H; Vandijck M; Martin JJ; De Deyn PP; Engelborghs S
    Alzheimers Dement; 2014 Oct; 10(5 Suppl):S290-8. PubMed ID: 24439167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
    Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
    J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
    Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol.
    Herbert MK; Kuiperij HB; Verbeek MM
    J Immunol Methods; 2012 Jul; 381(1-2):1-8. PubMed ID: 22542401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
    Nutu M; Zetterberg H; Londos E; Minthon L; Nägga K; Blennow K; Hansson O; Ohrfelt A
    Dement Geriatr Cogn Disord; 2013; 36(1-2):99-110. PubMed ID: 23860354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.